Your browser doesn't support javascript.
loading
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.
Winthrop, Kevin L; Yndestad, Arne; Henrohn, Dan; Danese, Silvio; Marsal, Sara; Galindo, Maria; Woolcott, John C; Jo, Hyejin; Kwok, Kenneth; Shapiro, Andrea B; Jones, Thomas V; Diehl, Annette; Su, Chinyu; Panés, Julian; Cohen, Stanley B.
Afiliación
  • Winthrop KL; School of Medicine, Oregon Health and Science University, 3375 SW Terwilliger Blvd, Portland, OR, 97239, USA. Winthrop@ohsu.edu.
  • Yndestad A; Pfizer Inc, Oslo, Norway.
  • Henrohn D; Pfizer AB, Sollentuna, Sweden.
  • Danese S; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Marsal S; Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
  • Galindo M; Rheumatology Department, Vall d'Hebron Hospital, Barcelona, Spain.
  • Woolcott JC; Rheumatology Unit, Hospital Universitario, 12 de Octubre, Madrid, Spain.
  • Jo H; Pfizer Inc, Collegeville, PA, USA.
  • Kwok K; Pfizer Inc, New York, NY, USA.
  • Shapiro AB; Pfizer Inc, New York, NY, USA.
  • Jones TV; Pfizer Inc, Peapack, NJ, USA.
  • Diehl A; Pfizer Inc, Collegeville, PA, USA.
  • Su C; Pfizer Inc, Collegeville, PA, USA.
  • Panés J; Pfizer Inc, Collegeville, PA, USA.
  • Cohen SB; IBD Unit, Gastroenterology Department, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Rheumatol Ther ; 10(2): 357-373, 2023 Apr.
Article en En | MEDLINE | ID: mdl-36526796
INTRODUCTION: This post hoc analysis evaluated influenza adverse events (AEs) across rheumatoid arthritis (RA), ulcerative colitis (UC), and psoriatic arthritis (PsA) tofacitinib clinical programs. METHODS: Available data from phase 1, randomized phase 2/3/3b/4 clinical trials (completed by 2018), and long-term extension (LTE) studies (up to May 2019) in patients with RA, UC, and PsA were included [randomized or Overall (phase 1-3b/4 and LTE studies) tofacitinib cohorts]. Incidence rates (IRs; events per 100 patient-years) of combined influenza AEs (seasons 2004/2005 to 2018/2019) were analyzed, including by tofacitinib dose [5 or 10 mg twice daily (BID)] and age (< 65 versus ≥ 65 years). Logistic regression models evaluated risk factors for influenza AEs in the RA Overall tofacitinib cohort. RESULTS: In randomized cohorts, combined influenza AE IRs were generally similar across tofacitinib, adalimumab, methotrexate, and placebo groups, across indications. Among Overall tofacitinib cohorts, combined influenza AE IRs with tofacitinib 5/10 mg BID, respectively, were higher in the UC (3.66/5.09) versus RA (2.38/2.19) and PsA (1.74/1.29) cohorts. IRs were generally similar across tofacitinib dose and age groups. Most influenza AEs were nonserious and did not require changes to tofacitinib treatment. Significant risk factors for influenza AEs in patients with RA were geographic region, baseline oral corticosteroid and methotrexate use, and tofacitinib dose. CONCLUSIONS: In the RA, UC, and PsA clinical programs, combined influenza AE IRs were highest in UC, while in each indication they were generally similar across tofacitinib, placebo, and comparator groups. Influenza AEs were predominantly nonserious and not associated with changes to tofacitinib treatment. TRIAL REGISTRATION NUMBERS: NCT01262118, NCT01484561, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT02147587, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02281552, NCT02187055, NCT02831855, NCT00413699, NCT00661661, NCT00787202, NCT01465763, NCT01458951, NCT01458574, NCT01470612, NCT01877668, NCT01882439, NCT01976364.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Rheumatol Ther Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Rheumatol Ther Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido